Effects of Aprotinin on Short-Term and Long-Term Outcomes After Coronary Artery Bypass Grafting Surgery

Annals of Thoracic Surgery

Volumn 89, Issue 5, 2010, Pages 1489-1495

  Wang, Xianqiang ^a   Zheng, Zhe ^a   Ao, Hushan ^a   Zhang, Shiju ^a   Wang, Yang ^a   Zhang, Hao ^a   Hu, Shengshou ^a  

^a FUWAI HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

APROTININ; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; NITRATE; HEMOSTATIC AGENT;

ADULT; ADVERSE OUTCOME; ANGIOCARDIOGRAPHY; ARTICLE; ARTIFICIAL VENTILATION; BRAIN DISEASE; CHINESE; COMA; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY BYPASS SURGERY; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEART ATRIUM FIBRILLATION; HUMAN; INTENSIVE CARE UNIT; KIDNEY FAILURE; LENGTH OF STAY; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PERIOPERATIVE PERIOD; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; SINGLE DRUG DOSE; STROKE; SURGICAL MORTALITY; SURGICAL RISK; TREATMENT OUTCOME; AGED; BLEEDING; CASE CONTROL STUDY; COHORT ANALYSIS; COMPARATIVE STUDY; CORONARY ARTERY DISEASE; FOLLOW UP; INTRAVENOUS DRUG ADMINISTRATION; METHODOLOGY; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; PATHOPHYSIOLOGY; PEROPERATIVE CARE; POSTOPERATIVE COMPLICATION; PROBABILITY; REFERENCE VALUE; RISK; RISK ASSESSMENT; STATISTICAL MODEL; SURVIVAL; TIME;

AGED; APROTININ; BLOOD LOSS, SURGICAL; CASE-CONTROL STUDIES; COHORT STUDIES; CORONARY ARTERY BYPASS; CORONARY DISEASE; FEMALE; FOLLOW-UP STUDIES; HEMOSTATICS; HOSPITAL MORTALITY; HUMANS; INFUSIONS, INTRAVENOUS; INTRAOPERATIVE CARE; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; POSTOPERATIVE COMPLICATIONS; PROBABILITY; REFERENCE VALUES; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 77953067298     PISSN: 00034975     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.athoracsur.2010.02.006     Document Type: Article

References (25)

1. Royston D., Bidstrup B.P., Taylor K.M., and Sapsford R.N. Effect of aprotinin on need for blood transfusion after repeat open-heart surgery. Lancet 2 (1987) 1289-1291
2. Havel m., Grabenwöger F., Schneider J., et al. Aprotinin does not decrease early graft patency after coronary artery bypass grafting despite reducing postoperative bleeding and use of donated blood. J Thorac Cardiovasc Surg 107 (1994) 807-810
3. Hayashida N., Isomura T., Sato T., Maruyama H., Kosuga K., and Aoyagi S. Effects of minimal-dose aprotinin on coronary artery bypass grafting. J Thorac Cardiovasc Surg 114 (1997) 261-269
4. Murkin J.M. Attenuation of neurologic injury during cardiac surgery. Ann Thorac Surg 72 (2001) S1838-S1844
5. Sedrakyan A., Treasure T., and Elefteriades J.A. Effect of aprotinin on clinical outcomes in coronary artery bypass graft surgery: a systematic review and meta-analysis of randomized clinical trials. J Thorac Cardiovasc Surg 128 (2004) 442-448
6. Poston R.S., White C., Gu J., et al. Aprotinin shows both hemostatic and antithrombotic effects during off-pump coronary artery bypass grafting. Ann Thorac Surg 81 (2006) 104-110
7. Royston D., Levy J.H., Fitch J., et al. Full-dose aprotinin use in coronary artery bypass graft surgery: an analysis of perioperative pharmacotherapy and patient outcomes. Anesth Analg 103 (2006) 1082-1088
8. Ronald A., and Dunning J. Does use of aprotinin decrease the incidence of stroke and neurological complications in adult patients undergoing cardiac surgery?. Interact Cardiovasc Thorac Surg 5 (2006) 767-773
9. Mangano D.T., Tudor I.C., Dietzel C., et al. The risk associated with aprotinin in cardiac surgery. N Engl J Med 354 (2006) 353-365
10. Mangano D.T., Miao Y., Vuylsteke A., et al. Mortality associated with aprotinin during 5 years following coronary artery bypass graft surgery. JAMA 297 (2007) 471-479
11. Kertai M.D., Varga K.S., Royston D., et al. Aprotinin and perioperative complications in cardiac surgery. J Cardiovasc Surg (Torino) 48 (2007) 761-772
12. Mouton R., Finch D., Davies I., Binks A., and Zacharowski K. Effect of aprotinin on renal dysfunction in patients undergoing on-pump and off-pump cardiac surgery: a retrospective observational study. Lancet 371 (2008) 475-482
13. Koster A., Buz S., Krabatsch T., et al. High-dose aprotinin effectively reduces blood loss during on-pump coronary artery bypass grafting with bivalirudin anticoagulation. J Thorac Cardiovasc Surg 135 (2008) 685-687
14. Pagano D., Howell N.J., Freemantle N., et al. Bleeding in cardiac surgery: the use of aprotinin does not affect survival. J Thorac Cardiovasc Surg 135 (2008) 495-502
15. Schneeweiss S., Seeger J.D., Landon J., and Walker A.M. Aprotinin during coronary-artery bypass grafting and risk of death. N Engl J Med 358 (2008) 771-783
16. Shaw A.D., Stafford-Smith M., White W.D., et al. The effect of aprotinin on outcome after coronary-artery bypass grafting. N Engl J Med 358 (2008) 784-793
17. Fergusson D.A., Hb́ert P.C., Mazer C.D., et al. A comparison of aprotinin and lysine analogues in high-risk cardiac surgery. N Engl J Med 358 (2008) 2319-2331
18. Kain K., Catto A.J., and Grant P.J. Impaired fibrinolysis and increased fibrinogen levels in South Asian subjects. Atherosclerosis 156 (2001) 457-461
19. Forouhi N.G., Rumley A., Lowe G.D., McKeigue P., and Sattar N. Specific elevation in plasma tissue plasminogen activator antigen concentrations in South Asians relative to Europeans. Blood Coagul Fibrinolysis 14 (2003) 755-760
20. El Rouby S., Mestres C.A., LaDuca F.M., and Zucker M.L. Racial and ethnic differences in warfarin response. J Heart Valve Dis 13 (2004) 15-21
21. Yu H.Y., Liu C.H., Chen Y.S., Wang S.S., Chu S.H., and Lin F.Y. Relationship of international normalized ratio to bleeding and thromboembolism rates in Taiwanese patients receiving vitamin K antagonist after mechanical valve replacement. J Formos Med Assoc 104 (2005) 236-243
22. Wang X., Zheng Z., Ao H., et al. A comparison before and after aprotinin was suspended in cardiac surgery: different results in the real world from a single cardiac center in China. J Thorac Cardiovasc Surg 138 (2009) 897-903
23. McEvoy M.D., Reeves S.T., Reves J.G., and Spinale F.G. Aprotinin in cardiac surgery: a review of conventional and novel mechanisms of action. Anesth Analg 105 (2007) 949-962
24. Khan T.A., Bianchi C., and Voisine P. Reduction of myocardial reperfusion injury by aprotinin after regional ischemia and cardioplegic arrest. J Thorac Cardiovasc Surg 128 (2004) 602-608
25. Lazar H.L., Bao Y., Tanzillo L., et al. Aprotinin decreases ischemic damage during coronary revascularization. J Card Surg 20 (2005) 519-523